Ethicann Pharmaceuticals

News

Ethicann Pharmaceuticals News & Publications

Catalent to Partner with Ethicann Pharmaceuticals on New Fast-Dissolve Cannabinoid-Based Treatment for Multiple Sclerosis Spasticity

Ethicann Pharmaceuticals Presenting at Opal Group Family Office and Private Wealth Management Forum July 18-20, 2022

Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain

PDF

Download "Ethicann news 2022.pdf"

About Ethicann Pharmaceuticals Inc.

Ethicann Pharmaceuticals is targeting several different large-market diseases for its THC+CBD ethical pharmaceutical drugs; namely and in order of launch, spasticity from multiple sclerosis, adult focal epilepsy, and chronic pain from cancer. Collectively, existing products for these indications are above USD $20 billion in current annual worldwide sales.

Currently, there is a high medical need to much better utilize the positive medical properties of cannabinoids. A more patient targeted therapy for different indications would potentially give suffering patients a big advantage that are currently treated suboptimally.

Ethicann Pharmaceuticals Inc., which follows this approach, was formed in May 2018 by experienced senior executives that had already worked successfully for a company developing cannabinoid products.

Ethicann Pharmaceuticals Inc.

7710 Woodmont Avenue, Suite 610
Bethesda, MD 20814

Phone: +1-301-529-6984

Monday - Friday: 9:00am - 5:00pm
Saturday - Sunday: Closed

pharmaceutical companies • pharma company • pharmaceutical industry • pharmaceutical care • healthcare pharmaceuticals • medical research companies